[September 24, 2014] |
|
Research and Markets: Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline 2014 - 5 Companies & 9 Drug Profiles
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/csmwtt/paroxysmal)
has announced the addition of the "Paroxysmal
Nocturnal Hemoglobinuria - Pipeline Review, H2 2014" report to
their offering.
This report provides an overview of the Paroxysmal Nocturnal
Hemoglobinuria's therapeutic pipeline.
This report provides comprehensive information on the therapeutic
development for Paroxysmal Nocturnal Hemoglobinuria, complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Paroxysmal Nocturnal Hemoglobinuria and special features
on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain ompetitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Scope
-
The report provides a snapshot of the global therapeutic landscape of
Paroxysmal Nocturnal Hemoglobinuria
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the therapeutics
development for Paroxysmal Nocturnal Hemoglobinuria and enlists all
their major and minor projects
-
The report summarizes all the dormant and discontinued pipeline
projects
-
A review of the Paroxysmal Nocturnal Hemoglobinuria products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Paroxysmal Nocturnal Hemoglobinuria pipeline on the
basis of target, MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Companies Involved in Therapeutics Development
-
Shire Plc
-
Alnylam Pharmaceuticals, Inc.
-
MABLife S.A.S
-
Omeros Corporation
-
Apellis Pharmaceuticals, Inc.
Drug Profiles
-
Recombinant Coversin
-
APL-2
-
OMS-721
-
Long Acting APL-1
-
Cp-40
-
ALN-CC5
-
Monoclonal Antibody for Paroxysmal Nocturnal Hemoglobinuria
-
MAT-303
-
C1 esterase inhibitor (human)
For more information visit http://www.researchandmarkets.com/research/csmwtt/paroxysmal
[ Back To TMCnet.com's Homepage ]
|